10x Genomics, CHUV Advance Precision Cancer Diagnostics
PLEASANTON, Calif., July 29, 2026 10x Genomics has entered a multi-year research collaboration with Lausanne University Hospital (CHUV) to...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PLEASANTON, Calif., July 29, 2026 10x Genomics has entered a multi-year research collaboration with Lausanne University Hospital (CHUV) to...
DARMSTADT, Germany & MINNEAPOLIS, June 25, 2026 Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire Bio-Techne...
LAGUNA HILLS, CALIFORNIA, April 29, 2026 PreludeDx has announced that the U.S. Food and Drug Administration (FDA) has granted...
SAN FRANCISCO | January 9, 2026 — GSK has entered into a five-year strategic collaboration and AI model licensing...
BRISBANE, California | January 7, 2026 — CareDx and 10x Genomics have announced the launch of ImmuneScape™, a multiomics...
MINNEAPOLIS, USA, and TEL AVIV, Israel, November 4, 2025 — Bio-Techne Corporation (NASDAQ: TECH) and Nucleai, an AI-driven precision-medicine...
